FDA’s Peptide Compounding Policy Reached White House Review—What That Does (and Does Not) Change
FDA’s peptide compounding policy reached White House regulatory review, but no new peptide access policy is publicly operative yet. As of October 24, 2026, the Office of Information and Regulatory Affairs (OIRA) lists an HHS/FDA action titled Interim Access Policy for Compounding Using Certain Peptides as Pending Review under Executive Order 12866. The official record says OIRA received it on October 14; the listing became publicly noted on October 15.
That confirms a procedural step: HHS/FDA submitted a policy action for centralized executive-branch review. It does not reveal the policy text, identify the covered substances, establish an effective date, or show that OIRA has concluded its review.
Quick answer: The October listing means a draft FDA action entered OIRA review. It does not mean the action was cleared, published, made effective, added any peptide to the 503A Bulks List, approved any drug, proved safety or effectiveness, or authorized unrestricted sale, compounding, prescribing, or use.
This article is educational only. It is not legal advice, medical advice, prescribing guidance, compounding guidance, dosing or administration guidance, sourcing or purchasing guidance, or a recommendation to use any peptide.
Executive review is an intermediate checkpoint. The public still needs the released FDA document to know the policy’s actual scope and conditions.
What is publicly confirmed about the FDA peptide compounding policy in 2026?
The public record confirms only a small set of facts, and those facts should be kept separate from speculation. OIRA’s live record identifies:
- Title: Interim Access Policy for Compounding Using Certain Peptides
- Agency: Department of Health and Human Services / Food and Drug Administration
- RIN: 0910-ZD94
- Stage: Notice
- Received by OIRA: October 14, 2026
- Status as of October 24, 2026: Pending Review
- Legal deadline: None listed
- Economically significant: No
The record does not attach the policy text. It does not name the peptides, salts, routes, preparations, quality standards, eligibility conditions, enforcement conditions, or implementation date that FDA may be considering.
That missing text is not a minor detail. It is the difference between knowing that a document exists and knowing what the document does.
What does Executive Order 12866 review mean?
Submission to OIRA means the draft action is undergoing centralized regulatory review before any public release or implementation that may follow. OIRA sits within the Office of Management and Budget in the Executive Office of the President. Under the Executive Order 12866 framework, it reviews certain agency regulatory actions and coordinates interagency review.
During review, OIRA and other executive-branch offices may examine the action’s rationale, legal and policy implications, costs and benefits where relevant, consistency with presidential priorities, and interactions with other agencies. The agency may revise the draft during that process.
OIRA review can end in more than one way. A review may be concluded, the action may be changed, or the agency may withdraw it. Even a concluded review does not tell readers the final operative details unless and until the agency releases the relevant document.
Evidence-literacy rule: A pending OIRA record proves that review is happening. It does not prove what the reviewers will accept or what FDA will ultimately publish.
What did the July 2026 advisory committee vote establish?
The July vote supplied non-binding advice on a different but related question: whether specified peptide bulk drug substances should be placed on the 503A Bulks List. On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee considered the free-base and acetate forms of seven peptide groups.
The committee favored inclusion for both reviewed forms of:
- BPC-157
- KPV
- TB-500
- MOTS-c
- Epitalon
- Semax
It did not favor inclusion for the reviewed free-base or acetate forms of emideltide, also called DSIP.
Those recommendations were non-binding. FDA’s own advisory-committee page says advisory committees provide independent expert advice and that their recommendations do not legally bind the agency.
The vote therefore created a meaningful administrative record, but it did not itself amend the 503A Bulks List. For the tallies and the substance-by-substance context, see PeptideBase’s post-meeting analysis of the July peptide votes. The earlier FDA peptide compounding review explainer covers the statutory question and FDA staff’s pre-meeting concerns.
Does the OIRA submission implement the July vote?
The title suggests a relationship to peptide compounding access, but the unpublished record does not prove that the draft adopts the committee’s recommendations. It is reasonable to see the October action as a later step in the same broad policy area. It is not responsible to infer the covered substances or final outcome from the title alone.
Until FDA releases the document, the draft might cover all, some, or none of the substances discussed in July. It might create conditions, exclusions, route limits, quality requirements, transition rules, reporting obligations, or a different structure entirely. The public listing does not answer those questions.
Reporting can describe what unnamed sources believe is in the draft. Only the released FDA document can establish its actual language.
What OIRA review does not change
Pending review changes the procedural status, not the legal or scientific status of the peptides. It is not any of the following:
| It is not… | Why not | |---|---| | OIRA policy clearance | The record still says Pending Review. | | Federal Register publication | No final or interim policy text is attached or cited as published. | | Addition to the 503A Bulks List | List inclusion requires its own FDA action; the July votes were advisory. | | FDA drug approval | Approval concerns a defined finished drug product, use, labeling, evidence, and manufacturing record. | | Proof of safety | A regulatory process step does not create clinical safety data. | | Proof of effectiveness | It does not establish that any peptide works for any condition. | | Unrestricted permission | Compounding remains subject to federal and state requirements, product-specific facts, and any conditions in an operative FDA policy. | | A buying or treatment recommendation | The record says nothing about what any person should obtain or use. |
The distinction matters for every substance named in the July meeting. Readers can review the entity pages for BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide/DSIP, but none of those evidence profiles becomes stronger merely because a policy draft entered executive review.
How does FDA’s Category 1 and Category 2 interim framework work?
FDA’s existing category system is an interim enforcement framework for nominated bulk drug substances; it is not the final 503A Bulks List. FDA’s compounding page describes three categories, of which Category 1 and Category 2 are the most relevant to access discussions.
Category 1
Category 1 historically covered substances that may be eligible for the 503A Bulks List, were nominated with enough information for FDA to evaluate, and did not appear on another list. Under FDA’s stated interim policy, the agency generally did not intend to take action against a compounder solely for using a Category 1 substance when the guidance conditions were met.
That is enforcement discretion, not a finding that the substance is approved, safe, effective, or finally included on the Bulks List.
Category 2
Category 2 covers nominated substances for which FDA identified potential significant safety risks pending further evaluation. FDA says the Category 1 enforcement approach does not apply to those substances and that compounding may be addressed under the agency’s general enforcement policies.
Again, Category 2 is an enforcement-policy classification, not a conventional drug-approval decision. FDA maintains a separate safety-risk page describing substances and the concerns it identified.
A 2025 cutoff now limits how the categories are used
FDA’s page, current as of May 14, 2026, adds an important qualification: the agency does not intend to place bulk drug substances nominated on or after January 7, 2025 into these interim categories. Older Category 1 substances may remain within the interim policy until FDA decides list inclusion or removes them based on information such as safety concerns.
This is why readers should not guess that the unpublished 2026 peptide policy simply moves names from one familiar bucket to another. Its relationship to the older category framework has to be read from the actual document.
What details remain unknown until FDA releases the document?
Nearly every practical detail remains undisclosed. The OIRA entry does not answer:
- which peptides or chemical forms are covered
- whether the policy tracks all or only part of the July committee recommendations
- whether free-base and acetate forms are treated differently
- which routes of administration, if any, fall within scope
- which compounders, prescriptions, or patient circumstances qualify
- what quality, testing, labeling, adverse-event, recordkeeping, or supplier controls apply
- whether FDA is describing enforcement discretion, list status, a transition period, or another mechanism
- when any policy would take effect
- whether the policy is temporary, conditional, or subject to expiration
- how federal policy would interact with state pharmacy and medical-practice rules
These questions cannot be answered by filling the gaps with the July vote, trade reporting, clinic claims, or social-media summaries. The unpublished text is not a regulatory Rorschach test, tempting though the internet finds that sport.
How should readers verify the final policy when it appears?
Read the released FDA document before drawing any access conclusion. A reliable status check should use this order:
- OIRA record: Has the status changed from Pending Review? Is there a concluded date or action?
- FDA source: Has FDA posted the policy, guidance, notice, or related webpage?
- Federal Register: Was a notice or rule published, and what effective date does it state?
- Substance scope: Are exact names, forms, salts, or active moieties listed?
- Conditions: Which routes, compounders, prescriptions, patients, quality controls, and records are covered?
- Legal effect: Is the document binding law, nonbinding guidance, or an enforcement-discretion policy?
- Separate product status: Does any claim improperly turn compounding policy into FDA approval or clinical proof?
For a broader method, see How to Evaluate Peptide Claims Online and what a “research use only” label does and does not mean.
Bottom line
FDA’s peptide compounding action reached OIRA review, but the public record still shows a pending, unpublished policy. That is a real procedural development after the July advisory votes. It is not the final access decision.
As of October 24, 2026, the defensible statement is narrow: OIRA is reviewing an HHS/FDA notice titled Interim Access Policy for Compounding Using Certain Peptides. The policy text and substance list are not public through the OIRA record, so its scope, conditions, routes, quality controls, effective date, and legal effect cannot be stated yet.
The next meaningful evidence is the released FDA document—not a headline that treats review as approval.
FAQ
Did the White House approve peptide compounding in October 2026?
No. OIRA’s record says the action is pending review. Submission for review is not clearance or approval.
Did FDA add BPC-157 or the other six peptide groups to the 503A Bulks List?
The October OIRA listing does not show that. The July committee recommendations were non-binding, and the OIRA record does not include a final FDA list action.
Which peptides are covered by the interim access policy?
The public OIRA record does not identify them. The July meeting involved BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide/DSIP, but that does not prove the unpublished policy covers the same set.
Does the policy prove these peptides are safe or effective?
No. Regulatory review and compounding policy do not replace clinical evidence or FDA approval of a finished drug product.
Is Category 1 the same as being on the 503A Bulks List?
No. Category 1 is part of an interim enforcement-discretion framework. It is not final Bulks List inclusion and is not FDA drug approval.
Where should the status be checked?
Check the live OIRA record, FDA’s human drug compounding pages, and any Federal Register publication. The released FDA document should control over summaries or speculation.
Sources
- Office of Information and Regulatory Affairs. Pending EO 12866 Regulatory Review: Interim Access Policy for Compounding Using Certain Peptides. RIN 0910-ZD94; checked October 24, 2026.
- U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. Meeting record and materials; checked October 24, 2026.
- U.S. Food and Drug Administration. Archived Pharmacy Compounding Advisory Committee webcasts: July 23, 2026 and July 24, 2026. Vote results were read into the meeting record.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Content current May 14, 2026; checked October 24, 2026.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current April 22, 2026; checked October 24, 2026.
- Executive Order 12866. Regulatory Planning and Review, October 4, 1993.